NCT01614470View on ClinicalTrials.gov

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

150 mg tablet, oral use, administered twice a day (q12h)

DRUG

Placebo

oral use, administered twice a day (q12h)

Trial Locations (12)

Unknown

Tampa

Atlanta

Chicago

Boston

Ann Arbor

Minneapolis

St Louis

Houston

Leuven

Lyon

Montpellier

Paris

All Listed Sponsors

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01614470 - Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation | Biotech Hunter | Biotech Hunter